01 November 2021: Database Analysis
Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer
Chanchan Gao E , Xuyu Gu A , Yan Chen C , Min Zhou D , Feng Jiang F , Shiya Zheng G*DOI: 10.12659/MSM.932275
Med Sci Monit 2021; 27:e932275
Figure 5 Assessment for chemotherapeutic responses to cisplatin and etoposide. (A) The estimated IC50 of cisplatin and etoposide to MCM-2. (B) The estimated IC50 of cisplatin and etoposide to EZH2. (C) The estimated IC50 of cisplatin and etoposide to CDKN2A. (D) The estimated IC50 of cisplatin and etoposide to CENPK. (E) The estimated IC50 of cisplatin and etoposide to CHEK1. (F) The estimated IC50 of cisplatin and etoposide to EXOSC2. (R software [Version 4.0.0, http://www.r-project.org]).